Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients

Tuesday, April 9, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster presented at AACR 2024 discusses the use of circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti-EZH2 treatment in patients with advanced solid tumors. This research stems from the CAIRE trial and highlights the potential of this biomarker in enhancing treatment monitoring. The findings suggest a promising avenue for improving patient management in oncology.
Price reaction · baseline $14.78 (2024-04-09T16:52:00.000Z) · hit during market hours · clean, no other VNRX news in the window
day 0 close · peak
-1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation at a major conference (AACR 2024) indicates significance.
  • Focus on a novel biomarker for monitoring treatment efficacy.
  • Potential to improve patient outcomes in advanced solid tumors.

Full Press Release Details

Poster titled: Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients: translational analyses from CAIRE trial
Presented at: AACR 2024
Salani et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the poster presented at AACR 2024?

The poster focuses on using H3K27me3 modified nucleosomes as a biomarker for monitoring anti-EZH2 treatment in advanced solid tumors.

What trial is the research based on?

The research is based on the CAIRE trial.

What is the significance of H3K27me3 nucleosomes?

H3K27me3 nucleosomes may improve the monitoring of treatment efficacy in cancer patients.

Who presented the research at AACR 2024?

The research was presented by Salani et al.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare EZH2 advanced solid tumors biomarker CAIRE trial AACR 2024
Last updated: Apr 9, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk